NRBO NeuroBo Pharmaceuticals Inc Total Business Assets
The development of drugs for metabolic disorders is not subject to GDP influence or seasonal fluctuations, confirming the resilience of NeuroBo Pharmaceuticals (NRBO). This chart illustrates the asset's market value reaching 24.26, alongside strict compliance with FDA bio-waste disposal regulations. The business relies on the search for advanced methods of regenerating damaged nerves to assist individuals with severe diabetes complications.
Analytical breakdowns and data insights for company NeuroBo (NRBO)
- stock value and consensus price forecast:
- market capitalization data:
- book capitalization information:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio NeuroBo Pharmaceuticals|NRBO - Long-Term Debt to Equity|Current Liabilities to Capital NeuroBo Pharma|NRBO - Company Debts|Debt to Book Value Ratio NeuroBo Pharma|NRBO - Company Long-Term Debts|Short-Term Debt NeuroBo Pharmaceuticals|Quick Ratio neurobopharma.com
- company profitability and valuation multiples indicators:
Basic company analysis:neurobopharma.com
Total assets represent the aggregate value of the company's resources, reverse-calculated via ROA to assess the fundamental basis, which allows an investor to determine business resilience to shocks through the analysis of asset and resource growth; for NeuroBo Pharmaceuticals (NRBO), this resilience is particularly high due to the non-cyclical nature of developing drugs for metabolic pathologies and the independence of R&D from macroeconomic fluctuations.
Direct competitors
Company Assets biogen.com (BIIB)|Aggregate Company Assets Neurocrine Biosciences, Inc.|Total Business Assets RGC (Regencell Bioscience Ltd)|Company Total Assets AXSM|ACAD - Company Assets|Xenon Pharmaceuticals - Cumulative Company Assets|Company Total Assets vikingtherapeutics.com VKTX|SUPN - Aggregate Company Assets|Aggregate Asset Value CPRX (Catalyst Pharma)|Denali Therapeutics Inc (DNLI) - Aggregate Company Assets|Company Assets Harmony Corp (HRMY)|Aggregate Company Assets Biohaven Ltd.|Total Business Assets AMLX (amylyx.com)|Company Total Assets TRVI|PRAX - Company Assets|Anavex Corp - Cumulative Company Assets|Company Total Assets CeriBell EEG CBLL|PRTA - Aggregate Company Assets|Aggregate Asset Value ALEC (Alector, Inc.)|Annexon (ANNX) - Aggregate Company Assets|Company Assets Omeros (OMER)|NGNE (Neurogene Corp) - Company Total Assets|Aggregate Company Assets ACIU|Aggregate Company Assets Voyager Therapeutics (VYGR)|NMRA - Company Assets|Scilex - Cumulative Company Assets|Aggregate Asset Value TVGN|ACOG - Aggregate Company Assets|Total Asset Value of Company CGTX|IKT: Company Total Assets|cassavasciences.com - Aggregate Asset Value|ASRT (Assertio Holdings) - Company Total Assets|Company Total Assets Coya|Aggregate Company Assets Vistagen Therapeutics (VTGN)|OVID (ovidrx.com) - Aggregate Asset Value|Aggregate Company Assets Acumen Pharmaceuticals ABOS|CRVO - Cumulative Company Assets|Alterity Therapeutics Ltd - Company Total Assets|CLNN - Company Total Assets|PEPG: Company Total Assets|Cumulative Company Assets Jupiter Neurosciences, Inc.|RLMD (Relmada Therapeutics) - Company Total Assets|Company Assets annovisbio.com ANVS|Cumulative Company Assets GRCE (Grace Therapeutics, Inc.)|Company Total Assets Firefly Neuroscience, Inc. (AIFF)|Klotho Neurosciences - Cumulative Company Assets|Aggregate Business Assets NRSN (NeuroSense Therapeutics Ltd)|Reviva Pharmaceuticals - Company Total Assets|Company Total Asset Base MetaVia Inc MTVA|NRXS: Company Total Assets|Cumulative Company Assets Helius Medical Technologies|PASG (Passage Bio Inc.) - Company Total Assets|Company Total Assets Neuphoria|Aggregate Company Assets Minerva Neurosciences (NERV)|Aggregate Company Assets ATHA (athira.com)|Aggregate Company Assets Addex Therapeutics Ltd ADXN|Company Total Asset Base Alzamend Neuro Inc. (ALZN)|CYCN - Aggregate Company Assets|PTIX (Protagenic Therapeutics) - Total Business Assets|pasitheaclinics.com (KTTA) - Aggregate Company Assets|Cortigent - Aggregate Asset Value|ATXI (Avenue Therapeutics, Inc.) - Company Total Assets|Aggregate Company Assets BCLI|Aggregate Company Assets Cara Therapeutics, Inc (CARA)|CHRO - Company Assets|Aggregate Company Assets Eliem Therapeutics Inc. ELYM|ITCI: Total Business Assets|Longboard Pharmaceuticals, Inc. - Company Total Assets|Company Assets Marinus Pharmaceuticals Inc|NKGN (NKGen) - Cumulative Company Assets|Sage Therapeutics Inc (SAGE) - Company Total Assets|Aggregate Company Assets Synaptogenix, Inc.|TRVN: Aggregate Asset Value|Aggregate Company Assets Vigil Neuroscience (VIGL)|WENA - Company Assets|Aggregate Company Assets Cerevel CERE